Pre-made Rozibafusp benchmark antibody ( Whole mAb Fusion, anti-ICOS therapeutic antibody, Anti-AILIM/CD278/CVID1 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Rozibafusp biosimilar, Whole mAb Fusion, Anti-ICOS Antibody: Anti-AILIM/CD278/CVID1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Rozibafusp alfa (previously AMG 570) is being developed by Amgen and AstraZeneca, for the treatment of systemic lupus erythematosus (SLE) and rheumatoid.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-499-1mg	1mg	Inquiry
GMP-Bios-ab-499-10mg	10mg	Inquiry
GMP-Bios-ab-499-100mg	100mg	Inquiry
GMP-Bios-ab-499-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Rozibafusp biosimilar, Whole mAb Fusion, Anti-ICOS Antibody: Anti-AILIM/CD278/CVID1 therapeutic antibody
INN Name	Rozibafusp
Target	ICOS
Format	Whole mAb Fusion
Derivation
Species Reactivity	Human
CH1 Isotype	IgG2
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	6x4t:BE:DF
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2018
Year Recommended	2019
Companies	Amgen
Conditions Approved	na
Conditions Active	Systemic lupus erythematosus
Conditions Discontinued	Rheumatoid arthritis
Development Tech	na